MediciNova, Inc.

NASDAQ:MNOV

Biotechnology

Healthcare
$1.33 -1.32%

-$0.02 today

Market cap
$68.14M
Beta
0.62
P/E (TTM)
-5.6
EPS (TTM)
-$0.24
52W Low $1.17High $1.96

Volume 0.12M

Average 0.04M

MNOV Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

MediciNova, Inc.NASDAQ: MNOV

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures turns negative

Q1 FY2026 capital expenditures was -$10.83K, compared with $1 a year earlier. Trailing-twelve-month capital expenditures was -$10.83K.

Context

  • Capital expenditures amounted to 0.0% of revenue in FY2025.
  • Capital expenditures increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly capital expenditures holds near -$10.83K or moves back toward the trailing-twelve-month quarterly average of -$2.71K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.83K-473.0% QoQ
Last fiscal yearDec 2025
$0+100.0% YoY
LTMMar 2026
-$10.83K+1111.5% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1082800.0%——
1 year+100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
+100.0%

Capital Expenditures vs competitors

How MNOV compares with its peers on the latest reported figures

  • MNOV's LTM Mar 2026 capital expenditures of $10.83K is the 8th largest of the 11 companies compared; the peer median is $155.5K.
  • Its year-over-year change of +1111.5% is the highest of 9, against a peer median of -45.3%.
  • Capital expenditures amounts to 1.8% of revenue for MNOV, versus a peer median of 4.8%.
MNOV Competitors Peer median
Capital Expenditures for MNOV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TCRXTScan Therapeutics, Inc.LTM Mar 2026$2.95M -36.7%+1.4%32.2%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$1.63M -19.2%-8.3%—
VXRTVaxart, Inc.LTM Mar 2026$463K -16.3%-75.3%0.2%
CBUSCibus, Inc.LTM Mar 2026$402K -53.8%-27.6%9.4%
XBITXBiotech Inc.LTM Mar 2026$195K -82.9%-20.9%—
IMUXImmunic, Inc.LTM Mar 2026$116K -58.6%+12.9%—
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$25K -61.5%-84.6%—
MNOVMediciNova, Inc.LTM Mar 2026$10.83K +1111.5%—1.8%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 ———
FBIOFortress Biotech, Inc.LTM Mar 2026$0 ——0.0%
BMEABiomea Fusion, Inc.LTM Mar 2026$0 +100.0%——
Peer median (excluding MNOV) $155.5K-45.3%-20.9%4.8%

Competitors are the stored peer set for MNOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(10.13M)(14.07M)(8.57M)(11.05M)(12M)
Depreciation & Amortization26.15K17.71K20.3K21.08K20.1K
Deferred Income Tax00000
Stock-Based Compensation1.72M642.52K710.71K1.19M829.1K
Change in Working Capital(1.21M)334.1K111.99K(979.56K)1.17M
Accounts Receivables00000
Inventory00000
Accounts Payables(1.03M)329.01K19.24K(312.35K)459.87K
Other Working Capital(181.42K)5.09K92.75K(667.21K)705.15K
Other Non-Cash Items216.93K163.19K297.49K173.32K173.68K
Operating Cash Flow(9.38M)(12.91M)(7.43M)(10.64M)(9.81M)
Capital Expenditures(28.73K)(5.01K)(21.3K)(895)0
Acquisitions (Net)05.01M000
Purchases of Investments0(59.88M)000
Sales of Investments019.88M39.93M00
Other Investing Activities0(5.01M)0198(2.9K)
Investing Cash Flow(28.73K)(40.01M)39.91M(697)(2.9K)
Debt Repayment00000
Common Stock Issued20.89M7.92K000
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(112.26K)000244.02K
Financing Cash Flow20.78M7.92K00244.02K
Effect of Forex Changes26.55K(16.81K)17.27K3.96K15.68K
Net Change in Cash11.39M(52.93M)32.49M(10.64M)(9.55M)
Free Cash Flow(9.41M)(12.92M)(7.45M)(10.64M)(9.81M)

MediciNova, Inc.

NASDAQ:MNOV

Intrinsic Alpha fair value

Locked

Current Price

$1.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.